Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

220 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-01

Study Completion Date

2022-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the efficacy and safety of vitreoretinal surgery combined with anti-VEGF therapy in the replacement of intraoperative PRP in PDR therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pars-plana Vitrectomy vs Panretinal Photocoagulation for Severe NPDR

NCT04103671

Non Proliferative Diabetic Retinopathy

RECRUITING NA

A Clinical Trial to Evaluate the Time Point of Anti-VEGF Pretreatment of PDR Based on Intraoperative FFA

NCT06300918

The Condition of Fundus Neovascularization

RECRUITING NA

PRP vs PRP+IVC for Severe nPDR

NCT03863535

Severe Nonproliferative Diabetic Retinopathy Diabetic Retinopathy Diabete Mellitus

UNKNOWN NA

Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy

NCT02911311

Proliferative Diabetic Retinopathy

UNKNOWN NA

Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy

NCT04674254

Proliferative Diabetic Retinopathy Vascular Endothelial Growth Factor Overexpression Diabetic Retinopathy

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anti-VEGF Proliferative Diabetic Retinopathy PRP Vitrectomy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

anti-VEGF

experimental group: vitreoretinal surgery combined with intraoperative anti-VEGF

Group Type EXPERIMENTAL

anti-VEGF

Intervention Type PROCEDURE

vitreoretinal surgery combined with intraoperative anti-VEGF

PRP

Control group: vitreoretinal surgery combined with intraoperative PRP

Group Type ACTIVE_COMPARATOR

PRP

Intervention Type PROCEDURE

vitreoretinal surgery combined with intraoperative PRP

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

anti-VEGF

vitreoretinal surgery combined with intraoperative anti-VEGF

Intervention Type PROCEDURE

PRP

vitreoretinal surgery combined with intraoperative PRP

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age≥18 years old;
2. type 1 or type 2 diabetes.
3. proliferative diabetic retinopathy with vitreous hemorrhage, and conservative treatment of vitreous hemorrhage without obvious absorption for 1 month requires vitreoretinal surgery;
4. The postoperative refractive medium is clear and the pupil is large enough to obtain sufficient clear fundus

Exclusion Criteria

1. Previously received panretinal photocoagulation or unfinished panretinal photocoagulation;
2. Pulling retinal detachment involving the macula or the presence of extensive fiber proliferation requires silicone oil filling;
3. anterior chamber neovascularization or neovascular glaucoma;
4. other vascular diseases such as retinal vein occlusion, arterial occlusion, etc;
5. received intraocular anti-VEGF therapy or triamcinolone acetonide treatment which are still in the treatment period.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No